Business description: Exelixis, Inc.

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Number of employees: 1,147

Sales by Activity: Exelixis, Inc.

Fiscal Period: December20202021202220232024

Discovery, Development & Commercialization of New Medicines for Difficult-To-Treat Cancers

988M 1.43B 1.61B 1.83B 2.17B
See all business segments

Geographical breakdown of sales: Exelixis, Inc.

Fiscal Period: December20202021202220232024

United States (U.S.)

753M 1.09B 1.41B 1.65B 1.82B

Europe

152M 302M 169M 145M 319M

Japan

83.02M 43.5M 28.73M 39.49M 27.08M
See all geographic segments

Managers: Exelixis, Inc.

Director TitleAgeSince
Chief Executive Officer 64 2010-07-21
Director of Finance/CFO 57 2015-07-14
Chief Tech/Sci/R&D Officer 58 2023-08-22
Chief Operating Officer - 2016-01-31
Investor Relations Contact - 2016-11-30
See EXELIXIS, INC. governance

Members of the board: Exelixis, Inc.

Manager TitleAgeSince
Director/Board Member 69 2004-01-31
Director/Board Member 80 2004-07-31
Chairman 76 1997-12-31
Director/Board Member 64 2010-07-21
Director/Board Member 54 2016-09-21
Director/Board Member 70 2018-04-04
Director/Board Member 69 2023-05-30
Director/Board Member 42 2023-05-30
Director/Board Member 66 2023-05-30
Director/Board Member 70 2024-01-04
Composition of the Board of Directors

Shareholders: Exelixis, Inc.

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
10.31 %
29,429,252 10.31 % 976 M $
BlackRock Advisors LLC
9.994 %
28,540,274 9.994 % 946 M $
Farallon Capital Management LLC
8.898 %
25,410,500 8.898 % 842 M $
Renaissance Technologies LLC
5.356 %
15,295,865 5.356 % 507 M $
11,443,668 4.007 % 379 M $
List of EXELIXIS, INC. shareholders

Company details: Exelixis, Inc.

Exelixis, Inc.

1851 Harbor Bay Parkway

94502, Alameda

+650-837-7000

http://www.exelixis.com
address Exelixis, Inc.(EXEL)

Bio Therapeutic Drugs

Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
+1.48%+4.54%+71.65%+88.27% 9.8B
-0.77%-2.20%+9.84%+98.50% 118B
-0.10%-5.13%-28.93%+8.03% 72.09B
-2.13%-3.83%+68.23%+140.90% 38.79B
-2.40%+1.89%+31.02%-22.46% 28.73B
+2.38%+3.29%+58.26%+12.45% 24.63B
+4.61%+2.25%+11.97%-30.27% 23.61B
-2.06%+6.27%+380.22%+952.71% 15.76B
+0.81%-0.80%+189.03%+244.83% 14.19B
+0.94%+8.59%-19.89%-31.61% 13.46B
Average +0.28%+1.41%+77.14%+146.14% 35.89B
Weighted average by Cap. -0.21%-1.00%+37.44%+98.99%
See all sector performances
Trading Rating
Investor Rating
ESG MSCI
BB
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
35.00USD
Average target price
36.89USD
Spread / Average Target
+5.39%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. EXEL Stock
  4. Company Exelixis, Inc.